Table 5.
Competing risks regression analysis of relapse and non-relapse mortality for all patients with de novo disease, using new cytogenetic risk groups
| Variable | HR for relapse | p | HR for NRM | p |
|---|---|---|---|---|
| Cytogenetics | ||||
| Standard-risk (reference) | 1.0 | 1.0 | ||
| Favorable | 0.3 | 0.006 | 0.6 | 0.2 |
| Adverse | 2.0 | 0.002 | 1.6 | 0.070 |
| Age | NS | 1.03 | 0.008 | |
| Disease/Stage | ||||
| AML in CR1 (reference) | 1.0 | 1.0 | ||
| CR≥1 | 1.8 | 0.009 | 1.7 | 0.058 |
| Active disease | 2.6 | <0.0001 | 1.0 | 0.9 |
| RA/RARS/RCMD | 0.4 | 0.041 | 1.6 | 0.3 |
| RAEB | 0.7 | 0.4 | 1.3 | 0.5 |
| mAML in CR1 | 0.9 | 0.7 | 1.6 | 0.078 |
| Match | ||||
| MRD (reference) | 1.0 | 1.0 | ||
| MUD | 0.8 | 0.2 | 2.6 | <0.0001 |
| Mismatched | 0.7 | 0.4 | 3.4 | 0.0002 |
| Conditioning | ||||
| Cy/TBI (reference) | 1.0 | 1.0 | ||
| Bu/Cy | 1.3 | 0.6 | 0.7 | 0.7 |
| Reduced intensity | 2.7 | .0005 | 0.1 | <0.0001 |
| GVHD prophylaxis | ||||
| CnI +/− Mtx* (reference) | 1.0 | 1.0 | ||
| CnI + Rapa +/− Mtx | 1.2 | 0.4 | 0.3 | 0.003 |
| TCD | 1.2 | 0.5 | 0.9 | 0.8 |
Graft source (bone marrow versus peripheral blood versus cord blood), CMV serostatus of donor and recipient (positive versus negative or unknown), female-to-male transplant, and year of transplant (in 10-year blocks) were not significant in this analysis.
HR indicates hazard ratio; NRM, non-relapse mortality; NS, non-significant; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; other abbreviations are explained in Table 1